Core Insights - Roluperidone is the only late-stage drug candidate for treating negative symptoms of schizophrenia, with consistent positive results from prior pivotal trials [1][4] - The first patient has been screened for a global Phase 3 clinical trial evaluating roluperidone as monotherapy for negative symptoms of schizophrenia, which currently has no FDA-approved treatments [2][4] Phase 3 Trial Overview - The Phase 3 trial will enroll approximately 380 patients across 40 clinical sites worldwide, including the US and Europe, following discussions with the FDA on trial design [3][5] - The trial aims to confirm the efficacy of roluperidone on primary negative symptoms at 12 weeks compared to placebo and evaluate long-term relapse of positive symptoms over an additional 40 weeks [5][8] Trial Design and Objectives - The trial consists of two phases: Phase A (12 weeks) focuses on the primary endpoint of change in the Marder Negative Symptoms Factor Score, while Phase B (40 weeks) compares relapse rates with commonly prescribed antipsychotic medications [6][7][8] - The design includes standardized assessments and caregiver engagement to minimize variability and maximize sensitivity to treatment effects [6] Expected Outcomes - Topline data from the 12-week Phase A portion is anticipated in the second half of 2027, which will provide insights into the primary efficacy endpoint [6][7]

Core Insights - The company Minerva Neurosciences, Inc. presented clinical data from a safety trial evaluating the co-administration of roluperidone and olanzapine at the 2026 Schizophrenia International Research Society Annual Congress [1][2] - The confirmatory Phase 3 trial is currently enrolling participants, with topline data expected in the second half of 2027 [1] Study Findings - The trial assessed potential interactions between roluperidone and olanzapine, a widely used antipsychotic, and found no clinically significant adverse effects [2] - There were no meaningful pharmacokinetic (PK) or pharmacodynamic (PD) changes observed during the combined administration of the two drugs [2] Presentation Details - The presentation titled "A Study of Roluperidone Coadministered with Olanzapine in Patients with Negative Symptoms of Schizophrenia" was delivered by Michael Davidson, MD, Chief Medical Officer of Minerva Neurosciences [2][6] - The presentation took place on March 26, 2026, during the Pharmaceutical Pipeline session [6]

Summary of Minerva Neurosciences Conference Call Company Overview - **Company**: Minerva Neurosciences (NasdaqCM:NERV) - **Focus**: Development of roluperidone, a potential treatment for schizophrenia, specifically targeting negative symptoms [1][2] Industry Context - **Schizophrenia Symptoms**: Schizophrenia is characterized by three types of symptoms: positive, negative, and cognitive deficits. Negative symptoms significantly impair quality of life and are currently not effectively treated by existing antipsychotics [2][3][4] - **Negative Symptoms**: These include avolition (lack of motivation), which is crucial for patient functioning and quality of life. Current treatments do not address these symptoms adequately, leading to a significant unmet medical need [5][6][7] Core Points and Arguments - **Treatment Gap**: There is no approved treatment for negative symptoms of schizophrenia in the U.S. as of now, and existing antipsychotics may worsen these symptoms [4][5] - **Clinical Trial Design**: The company emphasizes the need for innovative trial designs to assess the efficacy of treatments for negative symptoms, suggesting that traditional methods may not be suitable [8][9] - **Pharmacology of Roluperidone**: Roluperidone works through mechanisms that do not block dopamine, which is believed to help maintain stability in positive symptoms while improving negative symptoms [16][17] - **Efficacy Data**: In clinical trials, roluperidone showed significant improvements in negative symptoms and functioning, with a low relapse rate when used as monotherapy. The drug was well-tolerated with no significant side effects [22][24][23] Important Data Points - **Clinical Trial Results**: - The primary endpoint was assessed using the PANSS scale, with significant improvements noted at week 12. The 64 mg dose showed stronger effects compared to the 32 mg dose [19][20] - The first study had a p-value of 0.0001, indicating strong efficacy, while the second study showed a nominal improvement for the 64 mg dose [20][21] - **Patient Population**: Over 800 patients participated in the trials, with a focus on those with stable positive symptoms and significant negative symptoms [17] Regulatory Considerations - **FDA Interactions**: The company has engaged in discussions with the FDA regarding trial design and endpoints, aiming to establish a clear path for approval given the lack of existing treatments for negative symptoms [25][26] - **Study Design**: The upcoming study will compare roluperidone to commonly prescribed antipsychotics, using a double-dummy design to maintain blinding [28] Future Outlook - **Timeline for Results**: The first patient in the new study is expected to be enrolled in Q2 of the current year, with top-line results anticipated in the second half of next year [41][42] - **Regulatory Submission**: Following the results, the company plans to re-engage with the FDA regarding NDA submission [42] Additional Considerations - **Clinical Meaningfulness**: The company is working to establish clinically meaningful effect sizes in collaboration with the FDA, given the absence of approved treatments for negative symptoms [30][31] - **Relapse Assessment**: The study will include psychometric endpoints and hard clinical endpoints to assess relapse rates and overall patient safety [39][40]

Company Announcement - Minerva Neurosciences, Inc. will participate in The Stifel 2026 Virtual CNS Forum on March 17-18, 2026, with Remy Luthringer, PhD, serving as Executive Chairman & CEO [1] - The presentation is scheduled for March 18 at 8:30 AM ET, and a replay will be available for ninety days following the event [2] Company Overview - Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders [3] - The company is initiating a confirmatory Phase 3 trial with roluperidone aimed at addressing negative symptoms of schizophrenia [3]

Core Insights - Minerva Neurosciences, Inc. is set to initiate a confirmatory Phase 3 trial for roluperidone targeting negative symptoms of schizophrenia in Q2 2026, with topline data expected in the second half of 2027 [1][9] Business Updates - The company secured $80 million in gross proceeds from a private placement on October 23, 2025, with potential additional funding of up to $120 million contingent on the exercise of warrants [3][4] - Minerva has achieved alignment with the FDA regarding the trial design for the Phase 3 study of roluperidone, which aims to evaluate its efficacy against placebo in approximately 380 patients over a 12-week period [4][9] Financial Results - For Q4 2025, Minerva reported a net loss of $283.7 million, or $25.51 per share, compared to a net loss of $4.3 million, or $0.56 per share, in Q4 2024 [17][28] - Total liabilities increased to $233.8 million as of December 31, 2025, up from $62.8 million in 2024, primarily due to the issuance of convertible preferred stock and warrants [16][27] - Cash and cash equivalents rose to approximately $82.4 million at the end of 2025, compared to $21.5 million at the end of 2024, largely due to the recent financing [19]

Core Insights - Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders [3] - The company will participate in The Citizens Life Sciences Conference on March 10-11, 2026, with a presentation scheduled for March 10 at 9:35 AM ET [2] - Minerva is initiating a confirmatory Phase 3 trial with roluperidone aimed at treating negative symptoms of schizophrenia [3] Company Information - Minerva Neurosciences, Inc. is dedicated to developing product candidates specifically for CNS diseases [3] - The company’s Executive Chairman & CEO, Remy Luthringer, will represent Minerva at the upcoming conference [1] - A replay of the conference presentation will be available for ninety days on the company's Investors & Media Events webpage [2]

Company Overview - Minerva Neurosciences is focused on developing roluperidone as a treatment for negative symptoms in patients with schizophrenia, addressing a significant unmet medical need in this area [2][3]. Product Development - Roluperidone is positioned as potentially the first effective treatment specifically targeting negative symptoms associated with schizophrenia, a condition that has seen decades of research without successful drug development [3]. Leadership and Expertise - The company is supported by notable experts in the field, including Professor Gregory Strauss and Professor Brian Kirkpatrick, who have made significant contributions to the understanding and treatment of schizophrenia [4].

Summary of Minerva Neurosciences Conference Call Company Overview - **Company**: Minerva Neurosciences (NasdaqCM:NERV) - **Focus**: Development of roluperidone for treating negative symptoms in schizophrenia Key Points Discussed Industry Context - **Schizophrenia**: Affects approximately 83 million people globally, with about 3.4 million in the U.S. alone [doc id='13'][doc id='14'] - **Financial Burden**: Estimated at $34 billion annually in the U.S., making it a leading cause of functional disability [doc id='14'] - **Negative Symptoms**: These symptoms significantly impair social and occupational functioning, leading to poor quality of life [doc id='14'][doc id='18'] Roluperidone Development - **Unmet Need**: There is currently no FDA-approved treatment specifically for negative symptoms of schizophrenia, highlighting a significant treatment gap [doc id='19'] - **Clinical Trials**: Roluperidone is positioned as potentially the first effective treatment for negative symptoms, with ongoing Phase III trials [doc id='2'][doc id='5'] FDA Engagement - **Collaboration**: Minerva has had productive discussions with the FDA regarding the design of the Phase III trial, including the use of monotherapy for roluperidone [doc id='5'][doc id='10'] - **Study Design**: The trial will compare roluperidone monotherapy against standard antipsychotic care, focusing on both efficacy and safety [doc id='60'] Clinical Insights - **Negative Symptoms Definition**: Negative symptoms include avolition, asociality, anhedonia, blunted affect, and alogia, which are minimally responsive to current treatments [doc id='20'][doc id='24'] - **Avolition**: Identified as a central domain affecting other negative symptoms, with evidence suggesting that improving motivation can lead to broader improvements in negative symptoms [doc id='25'][doc id='30'] Trial Results and Efficacy - **Phase IIb Results**: Roluperidone showed significant effects on negative symptoms, particularly at the 64 mg dose, which was associated with a large effect size [doc id='48'] - **Functionality Improvement**: The Personal and Social Performance Scale (PSP) indicated improvements in functioning, although effect sizes were modest [doc id='49][doc id='50'] Future Directions - **Phase III Confirmatory Trial**: The trial will include a screening period to ensure the right patient population, focusing on those with stable positive and negative symptoms [doc id='56][doc id='58] - **Site Selection**: Emphasis on quality performance metrics and minimizing variability by limiting the number of clinical sites involved [doc id='65][doc id='68] Conclusion - **Overall Impact**: Roluperidone has demonstrated statistical significance in improving primary negative symptoms without exacerbating positive symptoms or causing significant side effects, marking a potential breakthrough in schizophrenia treatment [doc id='53][doc id='54]

Core Insights - Minerva Neurosciences, Inc. is hosting a virtual KOL event on February 3, 2026, to discuss the challenges of treating negative symptoms of schizophrenia and the upcoming Phase 3 trial of roluperidone [1][2] Company Overview - Minerva Neurosciences is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders, particularly targeting negative symptoms of schizophrenia with its product candidate roluperidone [9] Industry Context - Current antipsychotics do not adequately address negative symptoms of schizophrenia, which affects 50% to 60% of individuals with the disorder, highlighting an unmet medical need [2][8] - The FDA has recognized the lack of approved treatments specifically for negative symptoms and held a public meeting in August 2024 to discuss optimal clinical trial approaches [2][8] Expert Contributions - Gregory Strauss, PhD, and Brian Kirkpatrick, MD, MSPH, will provide insights during the KOL event, focusing on the patient burden of negative symptoms and the regulatory challenges in assessing these symptoms [1][4][5]

Core Insights - Minerva Neurosciences, Inc. has appointed Dr. Inderjit Kaul to its board of directors, who will also serve as a consultant for the clinical development of roluperidone [1][3] - The company successfully raised up to $200 million in a private placement to fund a Phase 3 trial for roluperidone, aimed at treating negative symptoms in schizophrenia [2] Company Developments - Dr. Kaul brings extensive experience in drug development, particularly in schizophrenia, having previously overseen the late-stage clinical development of Cobenfy at Bristol Myers Squibb [3] - The company plans to enhance its board with members experienced in schizophrenia clinical trials to support the Phase 3 trial of roluperidone [2] Clinical Context - Negative symptoms of schizophrenia, which include blunted affect and anhedonia, are a significant unmet medical need, with no FDA-approved treatments currently available for these symptoms [4][6] - Approximately 50% to 60% of individuals with schizophrenia experience primary negative symptoms, which do not respond to existing antipsychotic medications [6]